Quince Therapeutics, Inc. announced that its pivotal Phase 3 NEAT clinical trial for eDSP in Ataxia-Telangiectasia (A-T) has surpassed 75% enrollment. A total of 65 participants have been randomized in the study's targeted 86-patient primary analysis population.
This milestone signifies substantial progress in the clinical development of eDSP, the company's lead asset. The NEAT trial is evaluating the neurological effects of eDSP treatment in patients with A-T, a rare neurodegenerative disease with no approved treatments.
Achieving over 75% enrollment brings the company closer to completing the trial and subsequently reporting topline results. This advancement is a key step towards potential regulatory submissions and addressing the high unmet medical need in the A-T patient community.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.